Pharmafile Logo
Pharmafocus logo
Advanced Search

blood disorder

Showing 4 posts of 4 posts found.

Novartis presents strong results in rare blood disorder trials

June 10, 2016
Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder

Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …

News
amgen_flag

Amgen’s drug reduces rates of bleeding in rare childhood disorder

April 21, 2016
Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim

Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …

News

Novartis receives EU approval for blood disorder treatment in children

April 7, 2016
Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp

Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …

News
Targcept image

Targacept and Catalyst sign $100 million deal

March 9, 2015
Research and Development, Sales and Marketing CB 813d, PF-05280602, Targecept, blood disorder, catalyst biosciences

Targacept and Catalyst Biosciences have signed a merger agreement which will see them develop new treatment options for patients with …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025